RS58104B1 - Farmaceutske kombinacije za lečenje alchajmerove bolesti - Google Patents

Farmaceutske kombinacije za lečenje alchajmerove bolesti

Info

Publication number
RS58104B1
RS58104B1 RS20181571A RSP20181571A RS58104B1 RS 58104 B1 RS58104 B1 RS 58104B1 RS 20181571 A RS20181571 A RS 20181571A RS P20181571 A RSP20181571 A RS P20181571A RS 58104 B1 RS58104 B1 RS 58104B1
Authority
RS
Serbia
Prior art keywords
formic acid
water
azeotrope
extraction
disease
Prior art date
Application number
RS20181571A
Other languages
English (en)
Serbian (sr)
Inventor
Ellen Schmidt
Johan Areberg
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58104(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of RS58104B1 publication Critical patent/RS58104B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RS20181571A 2012-09-09 2013-09-06 Farmaceutske kombinacije za lečenje alchajmerove bolesti RS58104B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261698664P 2012-09-09 2012-09-09
US201361782084P 2013-03-14 2013-03-14
EP13759195.4A EP2892563B1 (en) 2012-09-09 2013-09-06 Pharmaceutical compositions for treating alzheimer's disease
PCT/EP2013/068516 WO2014037532A1 (en) 2012-09-09 2013-09-06 Methods of treating alzheimer's disease and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
RS58104B1 true RS58104B1 (sr) 2019-02-28

Family

ID=49118521

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20181571A RS58104B1 (sr) 2012-09-09 2013-09-06 Farmaceutske kombinacije za lečenje alchajmerove bolesti

Country Status (33)

Country Link
US (4) US9375418B2 (enExample)
EP (1) EP2892563B1 (enExample)
JP (2) JP6693744B2 (enExample)
KR (2) KR20150065680A (enExample)
CN (1) CN104619344A (enExample)
AP (1) AP2015008306A0 (enExample)
AU (1) AU2013311573B2 (enExample)
BR (1) BR112015005117B1 (enExample)
CA (1) CA2883751C (enExample)
CL (1) CL2015000578A1 (enExample)
CY (1) CY1121062T1 (enExample)
DK (1) DK2892563T3 (enExample)
EA (1) EA030448B1 (enExample)
ES (1) ES2703630T3 (enExample)
GE (1) GEP201706776B (enExample)
HR (1) HRP20182069T1 (enExample)
IL (1) IL237369B (enExample)
JO (1) JO3459B1 (enExample)
LT (1) LT2892563T (enExample)
MX (1) MX368305B (enExample)
MY (1) MY182539A (enExample)
NI (1) NI201500031A (enExample)
NZ (1) NZ630589A (enExample)
PL (1) PL2892563T3 (enExample)
PT (1) PT2892563T (enExample)
RS (1) RS58104B1 (enExample)
RU (1) RU2675786C2 (enExample)
SG (1) SG11201501774QA (enExample)
SI (1) SI2892563T1 (enExample)
SM (1) SMT201800678T1 (enExample)
TN (1) TN2015000076A1 (enExample)
TW (1) TWI632909B (enExample)
WO (1) WO2014037532A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節物質
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
JO3639B1 (ar) 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
HUE047208T2 (hu) 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
WO2016179569A1 (en) * 2015-05-07 2016-11-10 Axovant Sciences Ltd. Compositions and methods of treating a neurodegenerative disease
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
KR102473545B1 (ko) * 2016-04-26 2022-12-01 하. 룬드벡 아크티에셀스카브 파킨슨병 환자에서 낙상을 감소시키기 위한 아세틸콜린에스테라아제 억제제 및 아이달로피르딘의 용도
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
KR102015484B1 (ko) 2016-05-18 2019-08-28 수벤 라이프 사이언시스 리미티드 순수한 5-ht6 수용체 길항제와 아세틸콜린에스테라제 저해제의 조합물
CN106309436A (zh) * 2016-07-25 2017-01-11 宁波大学 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
CN107118146B (zh) * 2017-04-13 2019-09-03 宁波大学 一种6-溴色胺衍生物及其制备方法和用途
RS61704B1 (sr) * 2017-05-24 2021-05-31 H Lundbeck As Kombinacija antagonista 5-ht6 receptora i inhibitora acetilholinesteraze za upotrebu u lečenju alchajmerove bolesti kod subpopulacije pacijenata koji nose apoe4 alele
JP7413368B2 (ja) 2018-09-28 2024-01-15 ヤンセン ファーマシューティカ エヌ.ベー. モノアシルグリセロールリパーゼ調節因子
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
EP3960174B1 (en) 2020-08-28 2024-10-30 Westfälische Wilhelms-Universität Münster Parasympathetic active phenyl-glycosid-substituted hydroxy-methyl-piperidine and -pyrrolidine alkaloids for medicinal use
JP2026514626A (ja) * 2024-03-22 2026-05-13 クイーン アーリック マグネシウム・リドカイン組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597149A (en) 1969-04-29 1971-08-03 Showa Denko Kk Inhibition of gas-fume fading of dyed cellulose acetate material
FR2181559A1 (en) 1972-04-28 1973-12-07 Aec Chimie Organique Bio N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity
JPS5764632A (en) 1980-10-09 1982-04-19 Mitsui Toatsu Chem Inc Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
WO1995006638A1 (en) 1993-09-01 1995-03-09 Allelix Biopharmaceuticals Inc. Tryptamine analogs with 5-ht1d selectivity
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
KR20010040254A (ko) 1997-09-29 2001-05-15 스티븐 엘. 네스빗 아미노알킬페놀 유도체 및 관련 화합물
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
AU767009B2 (en) 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
HK1044539A1 (zh) 1999-01-13 2002-10-25 千年药品公司 作为趋化因子受体调节剂的官能化杂环
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
RU2252936C2 (ru) 2002-12-05 2005-05-27 Институт физиологически активных веществ РАН S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты)
PE20071143A1 (es) 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
JP2009541423A (ja) 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と5‐ht6レセプター親和性の化合物との組合せ
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
US20120184532A1 (en) * 2009-07-23 2012-07-19 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
MX2015002879A (es) 2015-07-06
US9375418B2 (en) 2016-06-28
CL2015000578A1 (es) 2015-05-15
TWI632909B (zh) 2018-08-21
TW201414474A (zh) 2014-04-16
JP6693744B2 (ja) 2020-05-13
TN2015000076A1 (en) 2016-06-29
EA201590353A1 (ru) 2016-03-31
KR102342127B1 (ko) 2021-12-21
KR20150065680A (ko) 2015-06-15
WO2014037532A1 (en) 2014-03-13
JP2019059760A (ja) 2019-04-18
NZ630589A (en) 2015-12-24
US20140073681A1 (en) 2014-03-13
RU2675786C2 (ru) 2018-12-25
IL237369A0 (en) 2015-04-30
DK2892563T3 (en) 2019-01-21
AU2013311573B2 (en) 2017-10-12
NI201500031A (es) 2016-02-15
US9687473B2 (en) 2017-06-27
PT2892563T (pt) 2019-01-10
US20160256437A1 (en) 2016-09-08
RU2015107877A (ru) 2016-10-27
JP2015528471A (ja) 2015-09-28
CA2883751C (en) 2020-11-24
AU2013311573A1 (en) 2015-03-12
LT2892563T (lt) 2019-01-10
AU2013311573A8 (en) 2015-03-19
IL237369B (en) 2018-11-29
HK1212217A1 (en) 2016-06-10
MX368305B (es) 2019-09-27
CY1121062T1 (el) 2019-12-11
US10660878B2 (en) 2020-05-26
MY182539A (en) 2021-01-25
US9789085B2 (en) 2017-10-17
KR20200137028A (ko) 2020-12-08
ES2703630T3 (es) 2019-03-11
BR112015005117A2 (pt) 2017-07-04
SMT201800678T1 (it) 2019-02-28
CN104619344A (zh) 2015-05-13
AP2015008306A0 (en) 2015-03-31
EP2892563A1 (en) 2015-07-15
SI2892563T1 (sl) 2019-02-28
US20180071254A1 (en) 2018-03-15
SG11201501774QA (en) 2015-05-28
CA2883751A1 (en) 2014-03-13
JO3459B1 (ar) 2020-07-05
BR112015005117B1 (pt) 2022-06-21
GEP201706776B (en) 2017-11-27
PL2892563T3 (pl) 2019-04-30
HRP20182069T1 (hr) 2019-02-08
EP2892563B1 (en) 2018-11-14
EA030448B1 (ru) 2018-08-31
US20160354343A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
RS58004B1 (sr) Fleksibilna matrica tkiva
CN103965950B (zh) 煤液化油中酚类化合物的分离方法
CN104048866B (zh) 一种烟草废料中多酚类物质的提取方法
RU2016112932A (ru) Способ удаления серы из метанола-сырца
Gromov et al. Regeneration of sulfuric acid from electrolyte waste of the copper-smelting plant using solvent extraction
CN112390705B (zh) 一种1,3-丁二醇脱味的纯化方法
CN103907802B (zh) 一种绿色净化大米的生产方法及其装置
CN106701153A (zh) 高酸原油脱酸工艺方法和脱酸装置
HRP20211461T1 (hr) Postupak ekstrakcije mirisnog ekstrakta uporabom alternativnog otapala u usporedbi s konvencionalnim otapalima
CN105218293A (zh) 一种分离甲苯和乙醇混合物的方法及装置
RS20040581A (enExample)
CN103951604A (zh) 一种吲哚分离与提纯的方法
CN100519427C (zh) 从含水物流中除去丙二醇和丙二醇醚
CA2842372A1 (en) Method and system for removal of dissolved organic compounds in process water
SA521422610B1 (ar) أنظمة وطرق لتحلية تركيبات مائية خلال التحلية الأيزوتروبية غير المتجانسة
CN106397183B (zh) 从生物质酸催化水解产物中分离乙酰丙酸、甲酸和糠醛的方法
CN201437536U (zh) 一种油品溶剂精制装置
CN104479659A (zh) 一种油基钻屑清洗和基础油回收方法
CN105152874B (zh) 一种生产二丙二醇甲醚的方法
RS20040255A (enExample)
CN103274922B (zh) 侧线精馏与共沸精馏集成分离丙酮-醋酸-水的方法
RS114504A (sr) Postupak za odstranjivanje hloroforma iz vode
CN103183589A (zh) 分离水和丙二醇单甲醚的方法
Ghanadzadeh et al. (Liquid+ liquid) equilibrium for ternary system of (water+ phenol+ cyclohexane) at T= 298.2 K
CN100415866C (zh) 从酒尾中提取酒用呈味呈香物质的方法